Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

EGFR-induced cytoskeletal changes drive complex cell behaviors: The tip of the iceberg.

Chiasson-MacKenzie C, McClatchey AI.

Sci Signal. 2018 Jan 30;11(515). pii: eaas9473. doi: 10.1126/scisignal.aas9473. Review.

PMID:
29382786
2.

Cell-Cell Contact and Receptor Tyrosine Kinase Signaling.

Chiasson-MacKenzie C, McClatchey AI.

Cold Spring Harb Perspect Biol. 2017 Jul 17. pii: a029215. doi: 10.1101/cshperspect.a029215. [Epub ahead of print]

PMID:
28716887
3.

NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin.

Chiasson-MacKenzie C, Morris ZS, Baca Q, Morris B, Coker JK, Mirchev R, Jensen AE, Carey T, Stott SL, Golan DE, McClatchey AI.

J Cell Biol. 2015 Oct 26;211(2):391-405. doi: 10.1083/jcb.201503081. Epub 2015 Oct 19.

4.

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.

Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Campreciós G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N.

Cell Rep. 2015 Mar 10. pii: S2211-1247(15)00173-4. doi: 10.1016/j.celrep.2015.02.027. [Epub ahead of print]

5.

Update from the 2013 International Neurofibromatosis Conference.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC.

Am J Med Genet A. 2014 Dec;164A(12):2969-78. doi: 10.1002/ajmg.a.36754. Epub 2014 Sep 24. No abstract available.

6.

ERM proteins at a glance.

McClatchey AI.

J Cell Sci. 2014 Aug 1;127(Pt 15):3199-204. doi: 10.1242/jcs.098343. Epub 2014 Jun 20.

7.

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA.

Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639.

8.

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H.

Am J Med Genet A. 2014 Mar;164A(3):563-78. doi: 10.1002/ajmg.a.36312. Epub 2014 Jan 17.

9.

Ezrin tunes the magnitude of humoral immunity.

Pore D, Parameswaran N, Matsui K, Stone MB, Saotome I, McClatchey AI, Veatch SL, Gupta N.

J Immunol. 2013 Oct 15;191(8):4048-58. doi: 10.4049/jimmunol.1301315. Epub 2013 Sep 16.

10.

Merlin/ERM proteins establish cortical asymmetry and centrosome position.

Hebert AM, DuBoff B, Casaletto JB, Gladden AB, McClatchey AI.

Genes Dev. 2012 Dec 15;26(24):2709-23. doi: 10.1101/gad.194027.112.

11.

ERM proteins.

McClatchey AI.

Curr Biol. 2012 Sep 25;22(18):R784-5. doi: 10.1016/j.cub.2012.07.057. No abstract available.

12.

Contact inhibition (of proliferation) redux.

McClatchey AI, Yap AS.

Curr Opin Cell Biol. 2012 Oct;24(5):685-94. doi: 10.1016/j.ceb.2012.06.009. Epub 2012 Jul 24. Review.

PMID:
22835462
13.

SPRED proteins provide a NF-ty link to Ras suppression.

McClatchey AI, Cichowski K.

Genes Dev. 2012 Jul 15;26(14):1515-9. doi: 10.1101/gad.197434.112.

14.

Spatial regulation of receptor tyrosine kinases in development and cancer.

Casaletto JB, McClatchey AI.

Nat Rev Cancer. 2012 May 24;12(6):387-400. doi: 10.1038/nrc3277. Review.

15.

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W 3rd, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M.

Am J Med Genet A. 2012 Jan;158A(1):24-41. doi: 10.1002/ajmg.a.34359. Epub 2011 Dec 2.

16.

Ezrin-mediated apical integrity is required for intestinal homeostasis.

Casaletto JB, Saotome I, Curto M, McClatchey AI.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11924-9. doi: 10.1073/pnas.1103418108. Epub 2011 Jul 5.

17.

Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment.

Heiska L, Melikova M, Zhao F, Saotome I, McClatchey AI, Carpén O.

Oncogene. 2011 Dec 15;30(50):4953-62. doi: 10.1038/onc.2011.207. Epub 2011 Jun 13.

PMID:
21666723
18.

The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex.

Gladden AB, Hebert AM, Schneeberger EE, McClatchey AI.

Dev Cell. 2010 Nov 16;19(5):727-39. doi: 10.1016/j.devcel.2010.10.008.

19.

Ezrin is highly expressed in early thymocytes, but dispensable for T cell development in mice.

Shaffer MH, Huang Y, Corbo E, Wu GF, Velez M, Choi JK, Saotome I, Cannon JL, McClatchey AI, Sperling AI, Maltzman JS, Oliver PM, Bhandoola A, Laufer TM, Burkhardt JK.

PLoS One. 2010 Aug 27;5(8):e12404. doi: 10.1371/journal.pone.0012404.

20.

Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver.

Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, McClatchey AI.

Genes Dev. 2010 Aug 15;24(16):1718-30. doi: 10.1101/gad.1938710. Epub 2010 Jul 30.

21.

Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.

Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E.

Cancer Res. 2010 May 1;70(9):3483-93. doi: 10.1158/0008-5472.CAN-09-3107. Epub 2010 Apr 20.

22.

Organizing the cell cortex: the role of ERM proteins.

Fehon RG, McClatchey AI, Bretscher A.

Nat Rev Mol Cell Biol. 2010 Apr;11(4):276-87. doi: 10.1038/nrm2866. Review. Erratum in: Nat Rev Mol Cell Biol. 2010 Sep;11(9):674.

23.

Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma.

Morris ZS, McClatchey AI.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9767-72. doi: 10.1073/pnas.0902031106. Epub 2009 Jun 1.

24.

The neurofibroma cell of origin: SKPs expand the playing field.

Morris ZS, McClatchey AI.

Cell Stem Cell. 2009 May 8;4(5):371-2. doi: 10.1016/j.stem.2009.04.010.

25.

Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex.

McClatchey AI, Fehon RG.

Trends Cell Biol. 2009 May;19(5):198-206. doi: 10.1016/j.tcb.2009.02.006. Epub 2009 Apr 1. Review.

26.

Ezrin and moesin function together to promote T cell activation.

Shaffer MH, Dupree RS, Zhu P, Saotome I, Schmidt RF, McClatchey AI, Freedman BD, Burkhardt JK.

J Immunol. 2009 Jan 15;182(2):1021-32.

27.

Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture.

Larsson J, Ohishi M, Garrison B, Aspling M, Janzen V, Adams GB, Curto M, McClatchey AI, Schipani E, Scadden DT.

Cell Stem Cell. 2008 Aug 7;3(2):221-7. doi: 10.1016/j.stem.2008.06.005.

28.

Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C.

Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. doi: 10.1038/ncponc1157. Epub 2008 Jun 17.

PMID:
18560388
29.

Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.

Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA.

Blood. 2008 May 1;111(9):4716-22. doi: 10.1182/blood-2007-10-113068. Epub 2008 Feb 25.

30.

Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing.

Cole BK, Curto M, Chan AW, McClatchey AI.

Mol Cell Biol. 2008 Feb;28(4):1274-84. Epub 2007 Dec 17.

31.

Neurofibromatosis.

McClatchey AI.

Annu Rev Pathol. 2007;2:191-216. Review.

PMID:
18039098
32.

Nf2/Merlin: a coordinator of receptor signalling and intercellular contact.

Curto M, McClatchey AI.

Br J Cancer. 2008 Jan 29;98(2):256-62. Epub 2007 Oct 30. Review.

33.

Contact-dependent inhibition of EGFR signaling by Nf2/Merlin.

Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI.

J Cell Biol. 2007 Jun 4;177(5):893-903.

34.

Microvilli defects in retinas of ezrin knockout mice.

Bonilha VL, Rayborn ME, Saotome I, McClatchey AI, Hollyfield JG.

Exp Eye Res. 2006 Apr;82(4):720-9. Epub 2005 Nov 10.

PMID:
16289046
35.

Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin.

McClatchey AI, Giovannini M.

Genes Dev. 2005 Oct 1;19(19):2265-77. Review.

36.

A mouse model recapitulating molecular features of human mesothelioma.

Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR.

Cancer Res. 2005 Sep 15;65(18):8090-5.

37.
38.

Comparative pathology of nerve sheath tumors in mouse models and humans.

Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M.

Cancer Res. 2004 May 15;64(10):3718-24.

39.

Ezrin...a metastatic detERMinant?

Curto M, McClatchey AI.

Cancer Cell. 2004 Feb;5(2):113-4. Review.

40.

Merlin and ERM proteins: unappreciated roles in cancer development?

McClatchey AI.

Nat Rev Cancer. 2003 Nov;3(11):877-83. doi: 10.1038/nrc1213. Review. No abstract available.

PMID:
14668818
41.

NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.

Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI.

Genes Dev. 2003 May 1;17(9):1090-100. Epub 2003 Apr 14.

42.

DOCK4, a GTPase activator, is disrupted during tumorigenesis.

Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA.

Cell. 2003 Mar 7;112(5):673-84.

43.

Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum.

Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, Marino S, Radovanovic I, Reilly K, Aldape K.

Oncogene. 2002 Oct 24;21(49):7453-63. Review.

44.

The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling.

Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI.

Dev Cell. 2001 Jul;1(1):63-72.

45.

Mouse models of neurofibromatosis.

McClatchey AI, Cichowski K.

Biochim Biophys Acta. 2001;1471(2):M73-80. Review. No abstract available.

PMID:
11342186
46.

Advances in neurofibromatosis 2 (NF2): a workshop report.

Lim DJ, Rubenstein AE, Evans DG, Jacks T, Seizinger BG, Baser ME, Beebe D, Brackmann DE, Chiocca EA, Fehon RG, Giovannini M, Glazer R, Gusella JF, Gutmann DH, Korf B, Lieberman F, Martuza R, McClatchey AI, Parry DM, Pulst SM, Ramesh V, Ramsey WJ, Ratner N, Rutkowski JL, Ruttledge M, Weinstein DE.

J Neurogenet. 2000 Jun;14(2):63-106. Review. No abstract available.

PMID:
10992163
47.

Neurofibromatosis type II: mouse models reveal broad roles in tumorigenesis and metastasis.

McClatchey AI.

Mol Med Today. 2000 Jun;6(6):252-3. Review. No abstract available.

PMID:
10840384
48.

Modeling metastasis in the mouse.

McClatchey AI.

Oncogene. 1999 Sep 20;18(38):5334-9. Review. No abstract available.

49.

Tumor suppressor mutations in mice: the next generation.

McClatchey AI, Jacks T.

Curr Opin Genet Dev. 1998 Jun;8(3):304-10. Review.

PMID:
9690995
50.

Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.

McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T.

Genes Dev. 1998 Apr 15;12(8):1121-33.

Supplemental Content

Loading ...
Support Center